AbbVie Inc (ABBV)vsIncyte Corporation (INCY)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
INCY
Incyte Corporation
$95.27
-3.86%
HEALTHCARE · Cap: $19.80B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 1041% more annual revenue ($61.16B vs $5.36B). INCY leads profitability with a 26.7% profit margin vs 6.9%. INCY appears more attractively valued with a PEG of 0.35. INCY earns a higher WallStSmart Score of 83/100 (A-).
ABBV
Buy63
out of 100
Grade: C+
INCY
Exceptional Buy83
out of 100
Grade: A-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Margin of Safety
+84.2%
Fair Value
$624.90
Current Price
$95.27
$529.63 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Growing faster than its price suggests
Every $100 of equity generates 31 in profit
Earnings expanding 83.8% YoY
Safe zone — low bankruptcy risk
Keeps 27 of every $100 in revenue as profit
Attractively priced relative to earnings
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
No major concerns identified
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : INCY
The strongest argument for INCY centers on PEG Ratio, Return on Equity, EPS Growth. Profitability is solid with margins at 26.7% and operating margin at 25.5%. Revenue growth of 20.9% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : INCY
No major red flags identified for INCY, but monitor valuation.
Key Dynamics to Monitor
ABBV profiles as a value stock while INCY is a growth play — different risk/reward profiles.
INCY carries more volatility with a beta of 0.86 — expect wider price swings.
INCY is growing revenue faster at 20.9% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
INCY scores higher overall (83/100 vs 63/100), backed by strong 26.7% margins and 20.9% revenue growth. Both earn "Exceptional Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Incyte Corporation
HEALTHCARE · BIOTECHNOLOGY · USA
Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?